Compass Therapeutics (NASDAQ:CMPX) Announces Quarterly Earnings Results, Hits Expectations

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) issued its earnings results on Thursday, May 8th. The company reported ($0.12) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.12), Zacks reports.

Compass Therapeutics Stock Up 4.0%

Shares of NASDAQ:CMPX traded up $0.08 during trading on Friday, reaching $2.10. 1,104,624 shares of the company's stock traded hands, compared to its average volume of 913,989. Compass Therapeutics has a fifty-two week low of $0.77 and a fifty-two week high of $4.08. The firm has a market cap of $290.39 million, a PE ratio of -5.68 and a beta of 1.40. The company has a 50-day simple moving average of $1.94 and a 200-day simple moving average of $2.10.

Insider Activity

In other news, insider Jonathan Anderman acquired 20,000 shares of the stock in a transaction that occurred on Monday, April 7th. The shares were bought at an average cost of $1.54 per share, for a total transaction of $30,800.00. Following the acquisition, the insider now owns 21,000 shares in the company, valued at approximately $32,340. This represents a 2,000.00% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Carl L. Gordon sold 3,571,428 shares of Compass Therapeutics stock in a transaction dated Wednesday, April 9th. The stock was sold at an average price of $1.59, for a total value of $5,678,570.52. The disclosure for this sale can be found here. Insiders own 29.80% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the company. Leerink Partners upgraded Compass Therapeutics from a "market perform" rating to an "outperform" rating and raised their target price for the stock from $4.00 to $6.00 in a research note on Wednesday, April 2nd. D. Boral Capital reaffirmed a "buy" rating and set a $32.00 price target on shares of Compass Therapeutics in a research report on Monday, April 28th. HC Wainwright reaffirmed a "buy" rating and set a $24.00 price target on shares of Compass Therapeutics in a research report on Monday, April 21st. Piper Sandler began coverage on Compass Therapeutics in a research report on Wednesday, February 19th. They set an "overweight" rating and a $12.00 price target on the stock. Finally, Guggenheim cut their price target on Compass Therapeutics from $12.00 to $10.00 and set a "buy" rating on the stock in a research report on Friday, May 9th. Eight equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Buy" and an average price target of $13.13.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.